Navigation Links
Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
Date:9/10/2009

tivator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding, AT-406 induces rapid degradation of cIAP-1/2 proteins and promotes apoptosis through activation of caspase-8 and the death-receptor complex.

AT-406 has demonstrated strong single-agent antitumor activity in multiple pre-clinical xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The company is headquartered in Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipeline includes the oral multi-IAP antagonist AT-406, and an HDM2-p53 inhibitor program.

For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com


'/>"/>
SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... January 22, 2015 Juvent Sports ( ... the 2015 PGA Merchandise Show to bestow a Juvent ... female amateur golfer, Arlene McKitrick. The award commemorated and ... golf tournament win. She won her first amateur tournament ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Tolerated at All Doses ... Tested - ... - Exploratory Analysis of Cytokine Profile Following Treatment Supports ... Calif. and BOSTON, Nov. 5 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a biopharmaceutical ...
... (OTC Bulletin,Board: CRDT), a leading healthcare staffing company, ... Vice President of Operations of Crdentia,s,newly acquired Florida, ... Mr. Jones joins Crdentia from ATS Health Services, ... staffing services with six offices in,Florida, one in ...
... are nation,s healthiest states; ... WASHINGTON, Nov. 5 The overall health of ... made in several key health,indicators, according to a ... Public Health Association (APHA) and Partnership,for Prevention(TM). The ...
... DIEGO, Nov. 5 ADVENTRX Pharmaceuticals,Inc. (Amex: ... on commercializing proprietary product candidates for the treatment,of ... M. Culley,ADVENTRX,s chief business officer, is scheduled to ... November 14th, 2007 at 11:30,a.m. Central European Time ...
... 5 Boston Scientific,Corporation (NYSE: BSX ) today ... of its Cardiac Surgery and Vascular Surgery,businesses to the ... The transaction will be for a cash price of ... 45-90 days, subject to regulatory,approvals and customary conditions. The ...
... TARRYTOWN, N.Y., Nov. 5 EpiCept Corporation,(Nasdaq: ... financial,results for the three and nine months ended September ... a net loss attributable to common,stockholders of $7.7 million, ... million, or $0.22 per basic and diluted share, for ...
Cached Medicine News:Health News:Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting 2Health News:Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting 3Health News:Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting 4Health News:Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting 5Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 2Health News:Crdentia Announces Appointment of Tim Jones to Senior Management Team 3Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 2Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 3Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 4Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 5Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 6Health News:2007 America's Health Rankings(TM) Show a Decline in the Overall Health of the Nation 7Health News:ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference 2Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 2Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 3Health News:Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses 4Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 2Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 3Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 4Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 5Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 6Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 7Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 8Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 9Health News:EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results 10
(Date:1/23/2015)... FORT MYERS, Fla. , Jan. 23, 2015  Today ... approval of Novartis, Bexsero® for the prevention of ... to 25. Bexsero and Pfizer,s vaccine Trumenba®, which received ... in helping prevent this devastating disease. ...
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
...   Shire plc (LSE: SHP, NASDAQ: ... that it has filed lawsuits in,the U.S. District Court ... Pharmaceuticals, LLC ("Amneal") and Sandoz, Inc.,("Sandoz") for infringement of ... initiated in response to Abbreviated New Drug,Applications ("ANDAs") filed ...
... Inc. (NYSE: ALR ) ("Alere") announced today ... $2.1 billion.  Jefferies Finance LLC, GE Capital Markets, Inc., ... joint lead arrangers for the credit facilities, and GE ... the lenders under the credit facilities. The ...
Cached Medicine Technology:Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2Alere Inc. Announces $2.1 Billion Credit Facilities 2
... is indicated for the treatment of ... as telangiectasia, rosacea, spider angiomas, cherry ... papulosis nigra and keratoses. Patented ... selection of handpieces maximizes versatility, compact ...
... DioLite XP is a semiconductor-based laser system representing ... high power (5 watts) for fast treatment of ... ScanLite XP scanner. High power and large ... DioLite XP laser is indicated for the treatment ...
The Perkins has been established for well over 20 years as a "world standard" for hand held applanation tonometers....
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
Medicine Products: